Sandoz Stays Shut Out On Combigan In US Until 2022

 
• By Aidan Fry

A US district court was right to bar Sandoz launching a generic version of Allergan’s Combigan glaucoma treatment due to limiting safety and efficacy clauses in three patents, the US Court of Appeals has confirmed.

Eye drops
Sandoz will likely have to wait until 2022 before bringing a generic of Combigan eye drops to the US market • Source: Shutterstock

More from Legal & IP

More from Generics Bulletin